KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Debt: 2016-2017

Historic Non-Current Debt for Arbutus Biopharma (ABUS) over the last 1 years, with Dec 2017 value amounting to $12.0 million.

  • Arbutus Biopharma's Non-Current Debt changed negligibly% to $12.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $12.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $12.0 million for FY2017, which is negligibly% changed negligibly from last year.
  • As of Q4 2017, Arbutus Biopharma's Non-Current Debt stood at $12.0 million, which was down 0.00% from $12.0 million recorded in Q3 2017.
  • Arbutus Biopharma's Non-Current Debt's 5-year high stood at $12.0 million during Q4 2016, with a 5-year trough of $12.0 million in Q4 2016.
  • Moreover, its 2-year median value for Non-Current Debt was $12.0 million (2017), whereas its average is $12.0 million.